Development Pipeline
Tempest is developing a first-in-class oncology pipeline of small molecule therapeutics with broad commercial potential. The product candidates are designed to treat cancer by direct tumor killing, activating tumor-specific immunity, or a combination of both mechanisms.
“HCC” hepatocellular carcinoma, “RCC” renal cell carcinoma, “CCA” cholangiocarcinoma
First in class if approved by FDA. 1 Pursuant to a collaboration with Roche; TPST retains all product rights.
Programs
TPST-1120 (PPARα antagonist)
A first-in-class antagonist selective for peroxisome proliferator-activated receptor alpha (PPARα). PPARα is a transcription factor that regulates fatty acid oxidation (FAO) and inflammation and is over-expressed in many cancers. Hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and renal cell carcinoma (RCC) all express high levels of PPARα and its multiple target genes. TPST-1120 has completed monotherapy dose escalation, and a Phase 1/1b study in combination with nivolumab (NCT03829436). The global randomized Phase 1b/2 study in combination with atezolizumab (TECENTRIQ®) and bevacizumab (Avastin®) in frontline patients with advanced hepatocellular carcinoma (HCC) pursuant to a collaboration with F. Hoffmann-La Roche Ltd. is fully enrolled and ongoing. Early positive results from the study demonstrated clinically meaningful improvement in multiple categories for TPST-1120 when combined with atezolizumab (TECENTRIQ®) and bevacizumab (Avastin®) in the randomized comparison, including: objective response rate; number of patients on treatment; and number of patients on study.
TPST-1495 (dual EP2/ep4 antagonist)
A first-in-class antagonist selective for two receptors in the prostaglandin (PGE2) pathway, EP2 and EP4. Prostaglandins are expressed by advancing tumors and signaling through both EP2 and EP4 drives both tumor growth and immune suppression. The EP2 and EP4 receptor targets are highly expressed in diverse malignancies, including colorectal, lung, gastric and endometrial cancers. TPST-1495 is progressing through Phase 1/1b monotherapy and combination studies.
TREX-1 (inhibitor)
A first-in-class inhibitor of the cytosolic dsDNA exonuclease TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition and has increased expression in tumors. An orally available TREX-1 inhibitor should preferentially localize activation of STING to the tumor microenvironment (TME) and initiate priming of tumor-specific cytolytic T cells broadly across distinct metastatic lesions having unique antigenic repertoires. Tempest is currently advancing the program through lead optimization.
OUR EXPANDED ACCESS POLICY (EAP) TO INVESTIGATIONAL DRUGS
- Tempest understands that there are times when an individual is unable to participate in a clinical trial, and other treatment options have been exhausted. In those cases, the individual's physician may choose to request access to an investigational drug outside of a clinical trial via what is often termed “Expanded Access” in the United States.
- At this time, participation in a clinical trial is the only way to gain access to Tempest’s investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, Tempest may review and update this policy on Expanded Access.